H. Lundbeck A/S

H. Lundbeck develops, produces and markets drugs for treating diseases of the central nervous system. Products include antidepressants for the treatment of depression, panic disorder, and prevention of relapse/recurrence. Antipsychotic products for psychotic disorders; schizophrenia, anxiety, restlessness and insomnia; treatment of psychotic disorders; acute psychotic episodes, exacerbation of psychotic disorders. Co.'s products inclue Cipralex®/Lexapro® for the treatment of depression and anxiety; Ebixa® for the treatment of Alzheimer's disease; Azilect® for the treatment of Parkinson's disease; Xenazine®, Sabril®, Saphris® Sycrest®, Onfi, and other.
  • TickerLUN
  • ISINDK0010287234
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark
Casper Blom ...
  • Derek Laliberté
  • Jan Erik Gjerland
  • Jannick Lindegaard Denholt
  • Patrik Brattelius
  • Tobias Kaj

Talking Points -

Industrivarden (Hold) Preview: Staying the course Value uplift of 1% in Q3e and 3.3% 2020e EPRA NAV premium of 35% ‘20e vs sector avg. at par

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Lundbeck - Focus to remain on underlying LT potential

Expecting a fairly mundane Q3’20 report Still see FY’20 guidance as attainable BUY reiterated, 12m TP lowered to DKK 250 (278)

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Sector Fast Comment - US presidential election vs healthcare sector

Key takeaways from expert speaker event on US politics Zooming in on healthcare vs the US election outcome Multiple possible outcomes: remain LT sector optimistic

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Lundbeck - ABGSC’s Danish large cap seminar feedback

COVID-19 unfortunately hampering some key activities …but Vyepti still holds solid LT growth potential A largely defensive play with attractive valuation

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Sector Report - Still a solid defensive play

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Sectors. We also focus on the Communications Sector as it has seen steady relative strength ranking (R...

Lundbeck(H) A S: 1 director sold

A director at Lundbeck(H) A S sold 5,000 shares at 242.240DKK and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Casper Blom ...
  • Derek Laliberté
  • Jan Erik Gjerland
  • Jannick Lindegaard Denholt
  • Patrik Brattelius
  • Tobias Kaj

Talking Points -

Industrivarden (Hold) Preview: Staying the course Value uplift of 1% in Q3e and 3.3% 2020e EPRA NAV premium of 35% ‘20e vs sector avg. at par

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Lundbeck - Focus to remain on underlying LT potential

Expecting a fairly mundane Q3’20 report Still see FY’20 guidance as attainable BUY reiterated, 12m TP lowered to DKK 250 (278)

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Sector Fast Comment - US presidential election vs healthcare sector

Key takeaways from expert speaker event on US politics Zooming in on healthcare vs the US election outcome Multiple possible outcomes: remain LT sector optimistic

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Lundbeck - ABGSC’s Danish large cap seminar feedback

COVID-19 unfortunately hampering some key activities …but Vyepti still holds solid LT growth potential A largely defensive play with attractive valuation

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Sector Report - Still a solid defensive play

Expert Corporate Governance Service (ECGS)

H. Lundbeck - AGM 24 March 2020

In general, H. Lundbeck ("Lundbeck") is in compliance with the Danish regulations relating to organisation and procedures of the Annual General Meeting. Under ITEMS 4.1 - 4.6 the (re-)election of the board of directors is proposed. In view of concerns over aggregate time commitments as well as other concerns, ECGS normally would have recommended opposition to the re-election of: Messrs. Lars Søren Rasmussen (ITEM 4.1), Lars Erik Holmqvist (ITEM 4.3), Jeremy Max Levin (ITEM 4.4) and Mr. Jeffrey Berkowitz (ITEM 4.5). However, considering that the proxy card does not permit this, it recommends ...

Expert Corporate Governance Service (ECGS)

H.Lundbeck, March 26 2019

In general, Lundbeck is in compliance with the Danish regulations relating to organisation and procedures of the Annual General Meeting. Under ITEM 4.1, it is proposed to re-appoint Mr. Lars Soren Rasmussen as Chairman of  the board of directors. Although he is considered independent, ECGS notes that Mr. Rasmussen is currently chairing the Company's remuneration committee, which is not in accordance with its guidelines. ECGS furthermore notes a lack of female representation (22%) on the board and based on its guidelines the re-election of the chairman of the chairmanship (performing the dutie...

Alexander Aukner ...
  • David Martinsson
  • Håkon Astrup
  • Jesper Ingildsen
  • Jørgen Lian
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Karl-Johan Bonnevier ...
  • Martin Arnell
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Viktor Trollsten

Northern Lights

Alexander Aukner ...
  • Joachim Gunell
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Frank Maaø ...
  • Håkon Astrup
  • Jesper Ingildsen
  • Martin Arnell
  • Nicolas McBeath
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Alexander Aukner ...
  • Håkon Astrup
  • Helene Kvilhaug Brøndbo
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Martin Huseby Karlsen
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Viktor Trollsten

Northern Lights

For H LUNDBECK A/S, the environment deterioration entails a downgrade to Neutral

H LUNDBECK A/S (DK), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener just confirmed the fundamental rating of 3 stars out of 4, as well as the stock market behaviour of the title as moderately risky. However, environmental deterioration penalises the general evaluation, which is downgraded to Neutral. As of the analysis date May 15, 2020, the closing price was DKK 244.80 and its expected value was estimated at DKK 232.88.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch